Brazil
Canada
Germany
Japan
Featured Content
Latest Press Releases
- Nov 16, 2022 Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
- Nov 16, 2022 Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
- Nov 10, 2022 Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
Statements
Named Patient Use Programs
Featured Videos
Corporate Brochure
Corporate Brochure
Fact Sheets & Downloads
Logo Download
Horizon Logo | Full Color
Horizon Logo | Full Color, White Text
Horizon Logo | White
Horizon Logo | Charcoal
If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com.
Media Inquiries
For U.S. media inquiries, contact:
Geoff Curtis
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
+1 (888) 506-2562
For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373